Amarin's Bleak Prospects vs. Novartis' Strong Investment Appeal
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10 hours ago
0mins
Should l Buy NVS?
Source: Fool
- Amarin's Declining Performance: Amarin's total revenue fell by 6.5% year-over-year to $213.6 million in fiscal 2025, despite a 22% stock price increase over the past year, indicating a weakening competitive position in the market.
- Cost-Cutting Initiatives: Amarin successfully reduced its net loss per share from $0.20 in 2024 to $0.09 in 2025 through workforce reductions, demonstrating the company's efforts to improve its financial health despite declining sales.
- Legal Dispute Risks: Amarin is engaged in a legal battle with Hikma Pharmaceuticals at the U.S. Supreme Court, and a favorable outcome could boost its stock price; however, the ongoing legal risks pose significant threats to its future.
- Novartis' Steady Growth: Novartis reported sales of $54.5 billion in 2025, an 8% increase, with earnings per share rising 15% to $8.98, showcasing its ability to sustain growth despite patent expirations, supported by a diverse product portfolio and a robust pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 166.870
Low
112.00
Averages
127.75
High
143.00
Current: 166.870
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amarin's Bleak Prospects vs. Novartis' Strong Investment Appeal
- Amarin's Declining Performance: Amarin's total revenue fell by 6.5% year-over-year to $213.6 million in fiscal 2025, despite a 22% stock price increase over the past year, indicating a weakening competitive position in the market.
- Cost-Cutting Initiatives: Amarin successfully reduced its net loss per share from $0.20 in 2024 to $0.09 in 2025 through workforce reductions, demonstrating the company's efforts to improve its financial health despite declining sales.
- Legal Dispute Risks: Amarin is engaged in a legal battle with Hikma Pharmaceuticals at the U.S. Supreme Court, and a favorable outcome could boost its stock price; however, the ongoing legal risks pose significant threats to its future.
- Novartis' Steady Growth: Novartis reported sales of $54.5 billion in 2025, an 8% increase, with earnings per share rising 15% to $8.98, showcasing its ability to sustain growth despite patent expirations, supported by a diverse product portfolio and a robust pipeline.
See More
Global ETF Surges as Investors Abandon U.S. Stocks
Investor Trends: Since the beginning of the year, investors have been moving away from U.S. stocks and ETFs, favoring safer assets like gold and silver, as well as international equities, due to concerns over U.S. economic policies and market volatility.
ETF Performance: The VanEck FTSE All-World ex-U.S. ETF (VEU) has outperformed U.S. equities, gaining over 9% year-to-date compared to the S&P 500's slight gain, with significant interest from institutional investors.
Sector Exposure: The VEU ETF shows a strong allocation towards financials and technology, with notable holdings in companies from Japan, the UK, and Canada, reflecting a diversified global investment strategy.
Market Outlook: Analysts suggest that the ongoing "Sell America" trend and the ETF's strong performance indicate a continued preference for international investments, as U.S. equities face challenges from rising debt and unpredictable tariff policies.
See More
Novartis Reaches Settlement with Henrietta Lacks' Family Over HeLa Cells
- Settlement Reached: Novartis has reached a confidential settlement with the family of Henrietta Lacks, marking a resolution to the controversy surrounding the use of her cells without consent for medical research, with both parties expressing satisfaction despite undisclosed financial terms, indicating a recognition of historical injustices.
- Legal Context: The Lacks family filed the lawsuit nearly 70 years after her death, arguing that companies profited from cells obtained without permission, reflecting the complexities of ethics and legality in the biotech industry, particularly regarding patient consent.
- Scientific Contributions: Lacks' HeLa cells are renowned for their ability to multiply indefinitely in laboratory conditions, advancing global vaccine and disease research, with the World Health Organization crediting them for significant breakthroughs in polio, HIV, and cancer research, highlighting the tension between scientific advancement and ethical considerations.
- Ongoing Legal Actions: In 2023, the Lacks family settled with Thermo Fisher Scientific, yet lawsuits against other pharmaceutical companies remain active, demonstrating the family's strong resolve in pursuing justice and compensation for the unauthorized use of Henrietta Lacks' cells.
See More
Novartis Completes Acquisition of Avidity Biosciences
- Acquisition Completed: Novartis has successfully acquired Avidity Biosciences, making it a wholly owned subsidiary, with a transaction value of approximately $12 billion, marking a strategic expansion into the neuromuscular disease sector.
- Pipeline Enhancement: Avidity's muscle-directed Antibody Oligonucleotide Conjugates platform and three late-stage programs will bolster Novartis's RNA therapeutics pipeline, with planned product launches before 2030 potentially unlocking multi-billion-dollar market opportunities.
- Sales Growth Outlook: This acquisition is expected to support Novartis in achieving a net sales CAGR of 5-6% from 2025 to 2030, further solidifying its market position in the biopharmaceutical industry.
- Positive Market Reaction: Following the acquisition, Avidity's shares have ceased trading on Nasdaq, and Novartis's market confidence has increased, with expectations of accelerating the development and launch of next-generation medicines.
See More
Novartis to Build Radioligand Therapy Facility in Texas
- New Facility Construction: Novartis plans to build a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, expected to be operational by 2028, further expanding its U.S. operations.
- Growing Market Demand: The new facility will primarily serve patients in the Southern U.S., as the use of radioligand therapy broadens with FDA approvals for earlier-line treatments and additional tumor types, likely enhancing the company's market share in this area.
- Investment Strategy: Novartis aims to invest $23 billion over the next 4-5 years to bolster its manufacturing and R&D capabilities in the U.S., with the construction of this new facility being a key part of that strategy to enhance overall production capacity.
- Integration with Existing Facilities: The new plant will complement Novartis' existing sites in New Jersey, Indiana, California, and the newly announced site in Florida, creating a more comprehensive radioligand therapy network to meet the increasing market demand.
See More
Novartis: A Top Stock for Retirement Investing
- Stable Income Source: Novartis has increased its dividends annually since 1996, demonstrating a solid underlying business that can provide a reliable income stream for investors, thereby enhancing the reliability of retirement portfolios.
- Strong Product Pipeline: The company currently boasts 15 brands, each generating over $1 billion in sales in 2025, showcasing its sustained competitiveness and long-term growth potential in the pharmaceutical industry.
- Patent Cliff Management: Despite facing patent expiration for its primary growth driver, Entresto, which led to a sales decline in 2025, Novartis still projects revenue growth in 2026, indicating its strong market adaptability.
- Innovation Culture Driving Growth: With numerous products in clinical trials, Novartis is expected to achieve new approvals and label expansions, further driving robust financial performance despite fierce competition in core therapeutic areas.
See More
Amarin's Bleak Prospects vs. Novartis' Strong Investment Appeal
- Amarin's Declining Performance: Amarin's total revenue fell by 6.5% year-over-year to $213.6 million in fiscal 2025, despite a 22% stock price increase over the past year, indicating a weakening competitive position in the market.
- Cost-Cutting Initiatives: Amarin successfully reduced its net loss per share from $0.20 in 2024 to $0.09 in 2025 through workforce reductions, demonstrating the company's efforts to improve its financial health despite declining sales.
- Legal Dispute Risks: Amarin is engaged in a legal battle with Hikma Pharmaceuticals at the U.S. Supreme Court, and a favorable outcome could boost its stock price; however, the ongoing legal risks pose significant threats to its future.
- Novartis' Steady Growth: Novartis reported sales of $54.5 billion in 2025, an 8% increase, with earnings per share rising 15% to $8.98, showcasing its ability to sustain growth despite patent expirations, supported by a diverse product portfolio and a robust pipeline.
See More
Global ETF Surges as Investors Abandon U.S. Stocks
Investor Trends: Since the beginning of the year, investors have been moving away from U.S. stocks and ETFs, favoring safer assets like gold and silver, as well as international equities, due to concerns over U.S. economic policies and market volatility.
ETF Performance: The VanEck FTSE All-World ex-U.S. ETF (VEU) has outperformed U.S. equities, gaining over 9% year-to-date compared to the S&P 500's slight gain, with significant interest from institutional investors.
Sector Exposure: The VEU ETF shows a strong allocation towards financials and technology, with notable holdings in companies from Japan, the UK, and Canada, reflecting a diversified global investment strategy.
Market Outlook: Analysts suggest that the ongoing "Sell America" trend and the ETF's strong performance indicate a continued preference for international investments, as U.S. equities face challenges from rising debt and unpredictable tariff policies.
See More
Novartis Reaches Settlement with Henrietta Lacks' Family Over HeLa Cells
- Settlement Reached: Novartis has reached a confidential settlement with the family of Henrietta Lacks, marking a resolution to the controversy surrounding the use of her cells without consent for medical research, with both parties expressing satisfaction despite undisclosed financial terms, indicating a recognition of historical injustices.
- Legal Context: The Lacks family filed the lawsuit nearly 70 years after her death, arguing that companies profited from cells obtained without permission, reflecting the complexities of ethics and legality in the biotech industry, particularly regarding patient consent.
- Scientific Contributions: Lacks' HeLa cells are renowned for their ability to multiply indefinitely in laboratory conditions, advancing global vaccine and disease research, with the World Health Organization crediting them for significant breakthroughs in polio, HIV, and cancer research, highlighting the tension between scientific advancement and ethical considerations.
- Ongoing Legal Actions: In 2023, the Lacks family settled with Thermo Fisher Scientific, yet lawsuits against other pharmaceutical companies remain active, demonstrating the family's strong resolve in pursuing justice and compensation for the unauthorized use of Henrietta Lacks' cells.
See More
Novartis Completes Acquisition of Avidity Biosciences
- Acquisition Completed: Novartis has successfully acquired Avidity Biosciences, making it a wholly owned subsidiary, with a transaction value of approximately $12 billion, marking a strategic expansion into the neuromuscular disease sector.
- Pipeline Enhancement: Avidity's muscle-directed Antibody Oligonucleotide Conjugates platform and three late-stage programs will bolster Novartis's RNA therapeutics pipeline, with planned product launches before 2030 potentially unlocking multi-billion-dollar market opportunities.
- Sales Growth Outlook: This acquisition is expected to support Novartis in achieving a net sales CAGR of 5-6% from 2025 to 2030, further solidifying its market position in the biopharmaceutical industry.
- Positive Market Reaction: Following the acquisition, Avidity's shares have ceased trading on Nasdaq, and Novartis's market confidence has increased, with expectations of accelerating the development and launch of next-generation medicines.
See More
Novartis to Build Radioligand Therapy Facility in Texas
- New Facility Construction: Novartis plans to build a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, expected to be operational by 2028, further expanding its U.S. operations.
- Growing Market Demand: The new facility will primarily serve patients in the Southern U.S., as the use of radioligand therapy broadens with FDA approvals for earlier-line treatments and additional tumor types, likely enhancing the company's market share in this area.
- Investment Strategy: Novartis aims to invest $23 billion over the next 4-5 years to bolster its manufacturing and R&D capabilities in the U.S., with the construction of this new facility being a key part of that strategy to enhance overall production capacity.
- Integration with Existing Facilities: The new plant will complement Novartis' existing sites in New Jersey, Indiana, California, and the newly announced site in Florida, creating a more comprehensive radioligand therapy network to meet the increasing market demand.
See More
Novartis: A Top Stock for Retirement Investing
- Stable Income Source: Novartis has increased its dividends annually since 1996, demonstrating a solid underlying business that can provide a reliable income stream for investors, thereby enhancing the reliability of retirement portfolios.
- Strong Product Pipeline: The company currently boasts 15 brands, each generating over $1 billion in sales in 2025, showcasing its sustained competitiveness and long-term growth potential in the pharmaceutical industry.
- Patent Cliff Management: Despite facing patent expiration for its primary growth driver, Entresto, which led to a sales decline in 2025, Novartis still projects revenue growth in 2026, indicating its strong market adaptability.
- Innovation Culture Driving Growth: With numerous products in clinical trials, Novartis is expected to achieve new approvals and label expansions, further driving robust financial performance despite fierce competition in core therapeutic areas.
See More
